Brokerage firm Jefferies Maintains its rating on Becton Dickinson and Co(NYSE:BDX). In a research note issued to the investors, the brokerage major Raises the price-target to $192.00 per share. The shares have been rated Buy. The rating by Jefferies was issued on Jul 28, 2016.
Becton Dickinson and Co (BDX) shares turned negative on Thursdays trading session with the shares closing down -4.25 points or -2.42% at a volume of 29,99,768. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $171.63. The peak price level was also seen at $171.63 while the days lowest was $166.35. Finally the shares closed at $171.53. The 52-week high of the shares is $177.775 while the 52-week low is $128.87. According to the latest information available, the market cap of the company is $36,399 M.
Becton Dickinson and Co has also declared a cash dividend of $0.6600 on Jul 26, 2016. The shares will quote ex-dividend on Sep 7, 2016 and the record date has been fixed on Sep 9, 2016. The dividend payable date has been fixed on Sep 30, 2016.
Becton Dickinson and Co(BDX) last announced its earnings results on May 5, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $3.07B. Analysts had an estimated revenue of $3.07B. Earnings per share were $2.18. Analysts had estimated an EPS of $2.02.
Several Insider Transactions has been reported to the SEC. On Jun 14, 2016, John E Gallagher (VP, Corp Finance and Treasurer) sold 1,931 shares at $169.87 per share price.Also, On Jun 8, 2016, Nabil Shabshab (Executive Vice President) sold 5,080 shares at $168.75 per share price.On May 18, 2016, Jeffrey S Sherman (Sr. VP and General Counsel) sold 34,373 shares at $166.27 per share price, according to the Form-4 filing with the securities and exchange commission.
Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.